Vaccination versus treatment of influenza in working adults: a cost-effectiveness analysis.

PURPOSE To determine the cost-effectiveness of influenza vaccination, antiviral therapy, or no intervention for healthy working adults, accounting for annual variation in vaccine efficacy. METHODS We conducted a cost-effectiveness analysis based on published clinical trials of influenza vaccine and antiviral drugs, incorporating 10 years of surveillance data from the World Health Organization. We modeled influenza vaccination, treatment of influenza-like illness with antiviral drugs, or both, as compared with no intervention, targeting healthy working adults under age 50 years in the general community or workplace. Outcomes included costs, illness days, and quality-adjusted days gained. RESULTS In the base case analysis, the majority of costs incurred for all strategies were related to lost productivity from influenza illness. The least expensive strategy varied from year to year. For the 10-year period, antiviral therapy without vaccination was associated with the lowest overall costs (234 US dollars per person per year). Annual vaccination cost was 239 US dollars per person, and was associated with 0.0409 quality-adjusted days saved, for a marginal cost-effectiveness ratio of 113 US dollars per quality-adjusted day gained or 41,000 US dollars per quality-adjusted life-year saved compared with antiviral therapy. No intervention was the most expensive and least effective option. In sensitivity analyses, lower vaccination costs, higher annual probabilities of influenza, and higher numbers of workdays lost to influenza made vaccination more cost-effective than treatment. If vaccination cost was less than 16 US dollars or time lost from work exceeded 2.4 days per episode of influenza, then vaccination was cost saving compared with all other strategies. CONCLUSION Influenza vaccination for healthy working adults is reasonable economically, and under certain circumstances is cost saving. Antiviral therapy is consistently cost saving.

[1]  Erry,et al.  Cost effectiveness of thrombolytic therapy with tissue plasminogen activator as compared with streptokinase for acute myocardial infarction. , 1995, The New England journal of medicine.

[2]  P. F. Adams,et al.  Current estimates from the National Health Interview Survey, 1994. , 1995, Vital and health statistics. Series 10, Data from the National Health Survey.

[3]  Effectiveness of live, attenuated intranasal influenza virus vaccine in healthy, working adults: a randomized controlled trial. , 1999, JAMA.

[4]  M. Meltzer,et al.  Effectiveness and cost-benefit of influenza vaccination of healthy working adults: A randomized controlled trial. , 2000, JAMA.

[5]  John J. Treanor,et al.  Efficacy and Safety of the Oral Neuraminidase Inhibitor Oseltamivir in Treating Acute Influenza , 2000 .

[6]  J. Mandel,et al.  Absenteeism among employees who participated in a workplace influenza immunization program. , 1998, Journal of occupational and environmental medicine.

[7]  G. Boivin,et al.  Predicting influenza infections during epidemics with use of a clinical case definition. , 2000, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[8]  J. Mullooly,et al.  Impact of epidemic type A influenza in a defined adult population. , 1980, American journal of epidemiology.

[9]  K. Nichol,et al.  Side effects associated with influenza vaccination in healthy working adults. A randomized, placebo-controlled trial. , 1996, Archives of internal medicine.

[10]  D. Pollack,et al.  Therapeutic efficacy of amantadine HCl and rimantadine HCl in naturally occurring influenza A2 respiratory illness in man. , 1969, The New England journal of medicine.

[11]  L. Brammer,et al.  Influenza surveillance--United States, 1992-93 and 1993-94. , 1997, MMWR. CDC surveillance summaries : Morbidity and mortality weekly report. CDC surveillance summaries.

[12]  K. Nichol,et al.  Cost-benefit analysis of a strategy to vaccinate healthy working adults against influenza. , 2001, Archives of internal medicine.

[13]  O. Keene,et al.  Diagnosis of influenza in the community: relationship of clinical diagnosis to confirmed virological, serologic, or molecular detection of influenza. , 2001, Archives of internal medicine.

[14]  N. Cox,et al.  Surveillance for influenza--United States, 1994-95, 1995-96, and 1996-97 seasons. , 2000, MMWR. CDC surveillance summaries : Morbidity and mortality weekly report. CDC surveillance summaries.

[15]  K. Neuzil,et al.  Influenza-associated morbidity and mortality in young and middle-aged women. , 1999, JAMA.

[16]  Kenneth J. Smith,et al.  Cost-effectiveness of newer treatment strategies for influenza. , 2002, The American journal of medicine.

[17]  P. Muennig,et al.  Cost-effectiveness of vaccination versus treatment of influenza in healthy adolescents and adults. , 2001, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[18]  K. Nichol,et al.  Influenza vaccine effectiveness in preventing hospitalizations and deaths in persons 65 years or older in Minnesota, New York, and Oregon: data from 3 health plans. , 2001, The Journal of infectious diseases.

[19]  D. Stott,et al.  Influenza Vaccination of Health Care Workers in Long-Term-Care Hospitals Reduces the Mortality of Elderly Patients , 1997, The Journal of infectious diseases.

[20]  P. Ward,et al.  Use of the oral neuraminidase inhibitor oseltamivir in experimental human influenza: randomized controlled trials for prevention and treatment. , 1999, JAMA.

[21]  L. Huson,et al.  Use of the selective oral neuraminidase inhibitor oseltamivir to prevent influenza. , 1999, The New England journal of medicine.

[22]  F. Hayden,et al.  Short-term treatment with zanamivir to prevent influenza: results of a placebo-controlled study. , 2000, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[23]  M. Rothberg,et al.  Management of influenza symptoms in healthy adults , 2003, Journal of General Internal Medicine.

[24]  M. Virtanen,et al.  Randomized, placebo-controlled double blind study on the efficacy of influenza immunization on absenteeism of health care workers. , 1999, The Pediatric infectious disease journal.

[25]  T. Szucs.  The socio-economic burden of influenza. , 1999, The Journal of antimicrobial chemotherapy.

[26]  W. Chua,et al.  Cost of treating influenza in emergency department and hospital settings. , 2000, The American journal of managed care.

[27]  L. Magder,et al.  The Guillain-Barré syndrome and the 1992-1993 and 1993-1994 influenza vaccines. , 1998, The New England journal of medicine.

[28]  M. Meltzer,et al.  The economic impact of pandemic influenza in the United States: priorities for intervention. , 1999, Emerging infectious diseases.

[29]  M. Steinhoff,et al.  Effectiveness of influenza vaccine in health care professionals: a randomized trial. , 1999, JAMA.

[30]  R. Reichman,et al.  A controlled trial of amantadine and rimantadine in the prophylaxis of influenza A infection. , 1982, The New England journal of medicine.

[31]  L. Simonsen,et al.  Pandemic versus epidemic influenza mortality: a pattern of changing age distribution. , 1998, The Journal of infectious diseases.

[32]  M. Mäkelä,et al.  Influenza vaccination among healthy employees: a cost-benefit analysis. , 1997, Scandinavian journal of infectious diseases.

[33]  K. Nichol,et al.  The health and economic benefits associated with pneumococcal vaccination of elderly persons with chronic lung disease. , 1999, Archives of internal medicine.

[34]  S. Trottier,et al.  Efficacy and safety of oseltamivir in treatment of acute influenza: a randomised controlled trial , 2000, The Lancet.

[35]  M. Gold.  Cost-effectiveness in health and medicine , 2016 .

[36]  D. Taira,et al.  Influenza Vaccination, Hospitalizations, and Costs Among Members of a Medicare Managed Care Plan , 2001, Medical care.

[37]  F. Hayden,et al.  Impact of zanamivir on antibiotic use for respiratory events following acute influenza in adolescents and adults. , 2000, Archives of internal medicine.

[38]  K. Nichol,et al.  The efficacy and cost effectiveness of vaccination against influenza among elderly persons living in the community. , 1994, The New England journal of medicine.

[39]  K. Nichol,et al.  The effectiveness of vaccination against influenza in healthy, working adults. , 1995, The New England journal of medicine.

[40]  L. Simonsen,et al.  The impact of influenza epidemics on hospitalizations. , 2000, The Journal of infectious diseases.

[41]  Christopher T. Hill.  The congressional Office of Technology Assessment , 1997 .

[42]  D. Campbell,et al.  Cost-effectiveness of the influenza vaccine in a healthy, working-age population. , 1997, Journal of occupational and environmental medicine.

[43]  P. J. Ryan,et al.  The impact of influenza and influenza-like illness on productivity and healthcare resource utilization in a working population. , 1998, Occupational medicine.

[44]  S. Weingarten,et al.  Do hospital employees benefit from the influenza vaccine? , 2007, Journal of General Internal Medicine.

[45]  Joel Huber,et al.  Economic Analysis of Influenza Vaccination and Antiviral Treatment for Healthy Working Adults , 2002, Annals of Internal Medicine.